The objectives of this Digital Learning Series are to help practitioners and clinicians Enhance survival of their patients with novel cancer immunotherapies Manage toxicities and immune injury.
Practice Changing Updates on Advanced and Intermediate HCC
Enhancing Survival with Cancer Immunotherapy
CME points available for Singaporean practitioners (subject to SMC approval).
Advanced HCC Module
Welcome and Introductions
Exploring the rationale for combination
immunotherapy in HCC
Latest Clinical Data for Combination of Immunotherapy and Targeted Therapy in Advanced HCC
Latest Clinical Data for Dual Immunotherapy
in Advanced HCC
Molecular Targeted Therapy in Advanced HCC: Is there still a role?
Management of toxicities and immune related AEs with systemic therapy in HCC
Management of hepatotoxicity with systemic therapy in HCC
Intermediate and Early HCC Module
Evolving landscape of loco regional and immunotherapy combination in intermediate HCC
Transition from loco regional to systemic therapy in intermediate-stage HCC
Adjuvant and neoadjuvant immunotherapy in
early stage HCC